Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2023

May 22, 2023

30198_dirs_2023-05-22_a5d10394-c04e-4b0a-95bb-2a7b33283116.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-05-18

Reporting Person: FOLETTA MARK G (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-18 Common Stock A 3306 $0.001 Acquired 7794 Direct
2023-05-18 Common Stock G 4488 $0.0 Disposed 3306 Direct
2023-05-18 Common Stock G 4488 $0.0 Acquired 59092 Indirect

Footnotes

F1: The RSU Award was granted on May 18, 2023 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2024 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.

F3: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.